Dianthus Therapeutics, Inc. · NASDAQ:DNTH

Savitz Ryan sold 114,367 Dianthus Therapeutics, Inc. shares (Form 4)

Traded Mar 31, 2026 · Filed Apr 1, 2026

On Mar 31, 2026, Savitz Ryan (EVP, CFO & CBO) sold 114,367 Dianthus Therapeutics, Inc. shares at an average US$83.00 for US$9.49M under a trading plan, leaving 0 shares. Filed Apr 1, 2026 (Form 4).

Sold: 114,367 shares
Price: US$83.00 average (US$78.33 to US$85.54)
Value: US$9.49M
Holding after: 0 shares
Trading plan: Yes (Made under a plan set in advance)
Role: EVP, CFO & CBO

The filing in full

Date	Security	Transaction	Shares	Price	Holding after	Ownership
Mar 31, 2026	Common Stock	Option exercise	74,367	US$8.44	74,367	Direct
Mar 31, 2026	Common Stock	Option exercise	40,000	US$17.88	114,367	Direct
Mar 31, 2026	Common Stock	Sale	1,390	US$78.33	112,977	Direct
Mar 31, 2026	Common Stock	Sale	21,825	US$78.86	91,152	Direct
Mar 31, 2026	Common Stock	Sale	1,485	US$80.25	89,667	Direct
Mar 31, 2026	Common Stock	Sale	800	US$81.36	88,867	Direct
Mar 31, 2026	Common Stock	Sale	2,366	US$82.84	86,501	Direct
Mar 31, 2026	Common Stock	Sale	59,800	US$83.90	26,701	Direct
Mar 31, 2026	Common Stock	Sale	19,469	US$84.57	7,232	Direct
Mar 31, 2026	Common Stock	Sale	7,232	US$85.54	0	Direct

Source

View original at SEC

Related